NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $6.00.

Several brokerages have recently commented on NBY. Zacks Investment Research cut NovaBay Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 17th. HC Wainwright set a $4.00 target price on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 6th.

Shares of NYSEAMERICAN:NBY opened at $1.80 on Wednesday. NovaBay Pharmaceuticals has a fifty-two week low of $1.75 and a fifty-two week high of $4.80.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Featured Article: Asset Allocation, Balancing Your Investments

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.